ISRG Intuitive Surgical | $452.29 +1.9% | 10/21/2026 | | Set Price Target | $473.00 ➝ $503.00 | Outperform | 00.00% | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 10/21/2026 |
LLY Eli Lilly and Company | $1,275.50 -2.4% | 10/21/2026 | | Boost Price Target | $1,309.00 ➝ $1,316.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 10/21/2026 |
KZIA Novogen | $7.81 -3.2% | 10/20/2026 | | Initiated Coverage | $30.00 | Outperform | 00.00% | View details for Leerink Partners rating of Novogen (NASDAQ:KZIA) on 10/20/2026 |
UTHR United Therapeutics | $587.50 +0.5% | 10/19/2026 | | Boost Price Target | $685.00 ➝ $725.00 | Outperform | 00.00% | View details for Leerink Partners rating of United Therapeutics (NASDAQ:UTHR) on 10/19/2026 |
TRAX First Tracks Biotherapeutics | $44.05 +2.1% | 10/16/2026 | | Boost Price Target | $70.00 ➝ $90.00 | Outperform | 00.00% | View details for Leerink Partners rating of First Tracks Biotherapeutics (NASDAQ:TRAX) on 10/16/2026 |
JNJ Johnson & Johnson | $264.13 -1.3% | 10/14/2026 | | Lower Price Target | $276.00 ➝ $272.00 | Outperform | 00.00% | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 10/14/2026 |
XRAY DENTSPLY SIRONA | $9.43 -0.7% | 10/14/2026 | | Lower Price Target | $14.00 ➝ $10.00 | Market Perform | 00.00% | View details for Leerink Partners rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 10/14/2026 |
NVST Envista | $23.62 -1.5% | 10/14/2026 | | Lower Price Target | $35.00 ➝ $32.00 | Outperform | 00.00% | View details for Leerink Partners rating of Envista (NYSE:NVST) on 10/14/2026 |
HSIC Henry Schein | $84.96 -1.2% | 10/14/2026 | | Set Price Target | $96.00 ➝ $92.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Henry Schein (NASDAQ:HSIC) on 10/14/2026 |
ALGN Align Technology | $154.51 -0.6% | 10/14/2026 | | Lower Price Target | $235.00 ➝ $215.00 | Outperform | 00.00% | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 10/14/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
CNTB Connect Biopharma | $0.77 +0.6% | 10/12/2026 | | Initiated Coverage | $4.00 | Outperform | 00.00% | View details for Leerink Partners rating of Connect Biopharma (NASDAQ:CNTB) on 10/12/2026 |
CVS CVS Health | $93.55 -1.0% | 10/12/2026 | | Lower Price Target | $119.00 ➝ $112.00 | Outperform | 00.00% | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 10/12/2026 |
EQ Equillium | $1.23 -3.1% | 10/12/2026 | | Initiated Coverage | $6.00 | Outperform | 00.00% | View details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 10/12/2026 |
NKTR Nektar Therapeutics | $37.22 -3.7% | 10/12/2026 | | Initiated Coverage | $130.00 | Outperform | 00.00% | View details for Leerink Partners rating of Nektar Therapeutics (NASDAQ:NKTR) on 10/12/2026 |
PTGX Protagonist Therapeutics | $138.43 -0.8% | 10/12/2026 | | Reiterated Rating | $150.00 ➝ $190.00 | Outperform | 00.00% | View details for Leerink Partners rating of Protagonist Therapeutics (NASDAQ:PTGX) on 10/12/2026 |
QTTB Q32 Bio | $8.65 -1.7% | 10/12/2026 | | Initiated Coverage | $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of Q32 Bio (NASDAQ:QTTB) on 10/12/2026 |
VERA Vera Therapeutics | $27.99 -3.6% | 10/12/2026 | | Initiated Coverage | $34.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Vera Therapeutics (NASDAQ:VERA) on 10/12/2026 |
ARCT Arcturus Therapeutics | $9.84 -8.3% | 10/9/2026 | | Boost Price Target | $13.00 ➝ $19.00 | Outperform | 00.00% | View details for Leerink Partners rating of Arcturus Therapeutics (NASDAQ:ARCT) on 10/9/2026 |
BSX Boston Scientific | $45.67 -0.7% | 10/9/2026 | | Lower Price Target | $60.00 ➝ $55.00 | | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 10/9/2026 |
IQV IQVIA | $279.47 +0.4% | 10/8/2026 | | Boost Price Target | $280.00 ➝ $310.00 | Outperform | 00.00% | View details for Leerink Partners rating of IQVIA (NYSE:IQV) on 10/8/2026 |
CRBU Caribou Biosciences | $0.53 -4.9% | 10/7/2026 | | Reiterated Rating | $4.00 ➝ $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Caribou Biosciences (NASDAQ:CRBU) on 10/7/2026 |
COR Cencora | $330.77 -2.3% | 10/7/2026 | | Boost Price Target | $380.00 ➝ $388.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cencora (NYSE:COR) on 10/7/2026 |
CRBU Caribou Biosciences | $0.53 -4.9% | 10/7/2026 | | Downgrade | $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Caribou Biosciences (NASDAQ:CRBU) on 10/7/2026 |
MCK McKesson | $1,000.53 -1.2% | 10/7/2026 | | Boost Price Target | $1,030.00 ➝ $1,070.00 | Outperform | 00.00% | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 10/7/2026 |
OABI OmniAb | $4.66 -2.5% | 10/7/2026 | | Boost Price Target | $10.00 ➝ $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of OmniAb (NASDAQ:OABI) on 10/7/2026 |
RCKT Rocket Pharmaceuticals | $2.29 -0.9% | 10/7/2026 | | Lower Price Target | $7.00 ➝ $4.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/7/2026 |
BMY Bristol Myers Squibb | $61.58 -2.3% | 10/5/2026 | | Downgrade | $73.00 ➝ $59.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Bristol Myers Squibb (NYSE:BMY) on 10/5/2026 |
ORIC Oric Pharmaceuticals | $13.17 -3.4% | 10/5/2026 | | Initiated Coverage | $26.00 | Outperform | 00.00% | View details for Leerink Partners rating of Oric Pharmaceuticals (NASDAQ:ORIC) on 10/5/2026 |
ZNTL Zentalis Pharmaceuticals | $2.21 -8.3% | 10/5/2026 | | Initiated Coverage | $4.00 ➝ $8.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 10/5/2026 |
TXG 10x Genomics | $71.55 +2.6% | 9/29/2026 | | Boost Price Target | $40.00 ➝ $90.00 | Market Perform | 00.00% | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 9/29/2026 |
TWST Twist Bioscience | $139.92 +3.3% | 9/29/2026 | | Boost Price Target | $160.00 ➝ $190.00 | Outperform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 9/29/2026 |
ILMN Illumina | $269.42 +0.0% | 9/29/2026 | | Boost Price Target | $220.00 ➝ $300.00 | Outperform | 00.00% | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 9/29/2026 |
BRKR Bruker | $57.59 +0.5% | 9/29/2026 | | Boost Price Target | $60.00 ➝ $80.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 9/29/2026 |
ACHC Acadia Healthcare | $31.51 -1.2% | 9/23/2026 | | Boost Price Target | $30.00 ➝ $33.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Acadia Healthcare (NASDAQ:ACHC) on 9/23/2026 |
ANAB AnaptysBio | $48.73 +1.3% | 9/23/2026 | | Lower Price Target | $90.00 ➝ $81.00 | Outperform | 00.00% | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 9/23/2026 |
CLDX Celldex Therapeutics | $29.25 +1.0% | 9/23/2026 | | Boost Price Target | $70.00 ➝ $88.00 | Outperform | 00.00% | View details for Leerink Partners rating of Celldex Therapeutics (NASDAQ:CLDX) on 9/23/2026 |
LXEO Lexeo Therapeutics | $2.80 -3.1% | 9/23/2026 | | Reiterated Rating | $15.00 | Outperform | 00.00% | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 9/23/2026 |
OBX Obsidian Therapeutics | $13.98 +0.3% | 9/22/2026 | | Initiated Coverage | $32.00 | Outperform | 00.00% | View details for Leerink Partners rating of Obsidian Therapeutics (NASDAQ:OBX) on 9/22/2026 |
BLSM BlossomHill Therapeutics | $14.63 -7.5% | 9/21/2026 | | Boost Price Target | $36.00 ➝ $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/21/2026 |
VRTX Vertex Pharmaceuticals | $523.93 -2.1% | 9/21/2026 | | Initiated Coverage | $594.00 | Outperform | 00.00% | View details for Leerink Partners rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 9/21/2026 |
$29.97 or $0 today (Ad) The 0DTE Game Plan normally sells for 29.97, but it is free today through this link.
Inside is a straightforward 3-step approach to trading same-day options, with entry, exit and max loss set before you ever place a trade. Plain English, no complicated math, done by market close.
The price may return to 29.97 as soon as tomorrow. Click here to claim your free copy before the price changes |
ELOX Eloxx Pharmaceuticals | $12.80 -2.4% | 9/18/2026 | | Set Price Target | $32.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eloxx Pharmaceuticals (NASDAQ:ELOX) on 9/18/2026 |
ARDT Ardent Health | $12.28 -0.7% | 9/18/2026 | | Reiterated Rating | $14.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ardent Health (NYSE:ARDT) on 9/18/2026 |
ELOX Eloxx Pharmaceuticals | $12.80 -2.4% | 9/18/2026 | | Upgrade | $32.00 | Strong-Buy | 00.00% | View details for Leerink Partners rating of Eloxx Pharmaceuticals (NASDAQ:ELOX) on 9/18/2026 |
ENTX Entera Bio | $2.92 -3.3% | 9/18/2026 | | Initiated Coverage | $9.00 | Outperform | 00.00% | View details for Leerink Partners rating of Entera Bio (NASDAQ:ENTX) on 9/18/2026 |
HCA HCA Healthcare | $469.45 +0.5% | 9/18/2026 | | Reiterated Rating | $492.00 | Outperform | 00.00% | View details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 9/18/2026 |
THC Tenet Healthcare | $268.13 -0.9% | 9/18/2026 | | Reiterated Rating | $309.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tenet Healthcare (NYSE:THC) on 9/18/2026 |
UHS Universal Health Services | $186.88 -0.7% | 9/18/2026 | | Boost Price Target | $198.00 ➝ $205.00 | Outperform | 00.00% | View details for Leerink Partners rating of Universal Health Services (NYSE:UHS) on 9/18/2026 |
TWST Twist Bioscience | $139.92 +3.3% | 9/17/2026 | | Boost Price Target | $120.00 ➝ $160.00 | Outperform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 9/17/2026 |
BBNX Beta Bionics | $19.16 -0.9% | 9/14/2026 | | Boost Price Target | $24.00 ➝ $27.00 | Outperform | 00.00% | View details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 9/14/2026 |
LRMR Larimar Therapeutics | $2.35 +3.5% | 9/14/2026 | | Initiated Coverage | $13.00 | Outperform | 00.00% | View details for Leerink Partners rating of Larimar Therapeutics (NASDAQ:LRMR) on 9/14/2026 |
PTCT PTC Therapeutics | $60.59 -3.9% | 9/14/2026 | | Initiated Coverage | $98.00 | Hold ➝ Outperform | 00.00% | View details for Leerink Partners rating of PTC Therapeutics (NASDAQ:PTCT) on 9/14/2026 |
RYTM Rhythm Pharmaceuticals | $89.27 -1.8% | 9/14/2026 | | Initiated Coverage | $133.00 | Outperform | 00.00% | View details for Leerink Partners rating of Rhythm Pharmaceuticals (NASDAQ:RYTM) on 9/14/2026 |
XERS Xeris Biopharma | $10.20 -6.1% | 9/10/2026 | | Boost Price Target | $12.00 ➝ $16.00 | Outperform | 00.00% | View details for Leerink Partners rating of Xeris Biopharma (NASDAQ:XERS) on 9/10/2026 |
BBOT BridgeBio Oncology Therapeutics | $2.66 -6.7% | 9/10/2026 | | Lower Price Target | $27.00 | Outperform | 00.00% | View details for Leerink Partners rating of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) on 9/10/2026 |
PHVS Pharvaris | $31.41 +2.4% | 9/9/2026 | | Boost Price Target | $50.00 ➝ $65.00 | Outperform | 00.00% | View details for Leerink Partners rating of Pharvaris (NASDAQ:PHVS) on 9/9/2026 |
EVMN Evommune | $5.09 -2.4% | 9/9/2026 | | Lower Price Target | $28.00 ➝ $22.00 | Outperform | 00.00% | View details for Leerink Partners rating of Evommune (NYSE:EVMN) on 9/9/2026 |
BLCO Bausch + Lomb | $17.44 +0.1% | 9/9/2026 | | Initiated Coverage | $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bausch + Lomb (NYSE:BLCO) on 9/9/2026 |
COLL Collegium Pharmaceutical | $22.96 -2.3% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Collegium Pharmaceutical (NASDAQ:COLL) on 9/9/2026 |
AMRX Amneal Pharmaceuticals | $20.38 -0.5% | 9/9/2026 | | Initiated Coverage | $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 9/9/2026 |
PHAT Phathom Pharmaceuticals | $5.74 -18.1% | 9/9/2026 | | Initiated Coverage | $10.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Phathom Pharmaceuticals (NASDAQ:PHAT) on 9/9/2026 |
HROW Harrow | $28.44 +1.0% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Harrow (NASDAQ:HROW) on 9/9/2026 |
VTRS Viatris | $18.00 -2.6% | 9/9/2026 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 9/9/2026 |
AMRX Amneal Pharmaceuticals | $20.38 -0.5% | 9/9/2026 | | Initiated Coverage | $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 9/9/2026 |
ANIP ANI Pharmaceuticals | $72.61 -1.5% | 9/9/2026 | | Initiated Coverage | $104.00 | Outperform | 00.00% | View details for Leerink Partners rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 9/9/2026 |
BLCO Bausch + Lomb | $17.44 +0.1% | 9/9/2026 | | Initiated Coverage | $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bausch + Lomb (NYSE:BLCO) on 9/9/2026 |
COLL Collegium Pharmaceutical | $22.96 -2.3% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Collegium Pharmaceutical (NASDAQ:COLL) on 9/9/2026 |
HROW Harrow | $28.44 +1.0% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Harrow (NASDAQ:HROW) on 9/9/2026 |
MRK Merck & Co., Inc. | $145.25 -1.4% | 9/9/2026 | | Boost Price Target | $127.00 ➝ $161.00 | Outperform | 00.00% | View details for Leerink Partners rating of Merck & Co., Inc. (NYSE:MRK) on 9/9/2026 |
NAUT Nautilus Biotechnology | $3.24 +24.6% | 9/9/2026 | | Initiated Coverage | $4.00 | Outperform | 00.00% | View details for Leerink Partners rating of Nautilus Biotechnology (NASDAQ:NAUT) on 9/9/2026 |
PCRX Pacira BioSciences | $36.42 +0.2% | 9/9/2026 | | Initiated Coverage | $28.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Pacira BioSciences (NASDAQ:PCRX) on 9/9/2026 |
PHAT Phathom Pharmaceuticals | $5.74 -18.1% | 9/9/2026 | | Initiated Coverage | $10.00 | Hold | 00.00% | View details for Leerink Partners rating of Phathom Pharmaceuticals (NASDAQ:PHAT) on 9/9/2026 |
TEVA Teva Pharmaceutical Industries | $39.39 -2.0% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Teva Pharmaceutical Industries (NYSE:TEVA) on 9/9/2026 |
VTRS Viatris | $18.00 -2.6% | 9/9/2026 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 9/9/2026 |
SPRY ARS Pharmaceuticals | $4.03 -6.7% | 9/8/2026 | | Set Price Target | $15.00 | | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/8/2026 |
BLSM BlossomHill Therapeutics | $14.63 -7.5% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/1/2026 |
LTGO Latigo Biotherapeutics | $15.02 -9.4% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of Latigo Biotherapeutics (NASDAQ:LTGO) on 9/1/2026 |
BLSM BlossomHill Therapeutics | $14.63 -7.5% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/1/2026 |
LTGO Latigo Biotherapeutics | $15.02 -9.4% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of Latigo Biotherapeutics (NASDAQ:LTGO) on 9/1/2026 |
ATTO Attovia Therapeutics | $13.83 -4.6% | 8/31/2026 | | Initiated Coverage | $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Attovia Therapeutics (NASDAQ:ATTO) on 8/31/2026 |
SCTX Scribe Therapeutics | $15.40 -14.3% | 8/18/2026 | | Initiated Coverage | $37.00 | Outperform | 00.00% | View details for Leerink Partners rating of Scribe Therapeutics (NASDAQ:SCTX) on 8/18/2026 |
REGN Regeneron Pharmaceuticals | $805.02 -1.7% | 8/17/2026 | | Boost Price Target | $641.00 ➝ $824.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 8/17/2026 |
FRNM Freenome | $12.77 -2.5% | 8/14/2026 | | Initiated Coverage | $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of Freenome (NASDAQ:FRNM) on 8/14/2026 |
LGND Ligand Pharmaceuticals | $303.53 -1.4% | 8/14/2026 | | Initiated Coverage | $330.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ligand Pharmaceuticals (NASDAQ:LGND) on 8/14/2026 |
SMMT Summit Therapeutics | $15.47 -0.5% | 8/12/2026 | | Upgrade | $12.00 ➝ $13.00 | Underperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Summit Therapeutics (NASDAQ:SMMT) on 8/12/2026 |
CAH Cardinal Health | $249.47 -2.4% | 8/11/2026 | | Set Price Target | $292.00 | | 00.00% | View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 8/11/2026 |
TENX Tenax Therapeutics | $1.72 -2.3% | 8/11/2026 | | Set Price Target | $4.00 | | 00.00% | View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 8/11/2026 |
IPHA Innate Pharma | $1.50
| 8/11/2026 | | Upgrade | $4.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Innate Pharma (NASDAQ:IPHA) on 8/11/2026 |
NTRA Natera | $403.95 +0.6% | 8/7/2026 | | Set Price Target | $330.00 | | 00.00% | View details for Leerink Partners rating of Natera (NASDAQ:NTRA) on 8/7/2026 |
AKBA Akebia Therapeutics | $0.57 +0.8% | 8/7/2026 | | Downgrade | $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Akebia Therapeutics (NASDAQ:AKBA) on 8/7/2026 |
HALO Halozyme Therapeutics | $125.63 +0.9% | 8/7/2026 | | Upgrade | $83.00 ➝ $110.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 8/7/2026 |
Financial legend: “This is bad, really bad...” (Ad) Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit.
Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks. See Martin Weiss's full warning before this risk spreads further |
GDRX GoodRx | $3.54 -2.2% | 8/6/2026 | | Set Price Target | $5.00 | | 00.00% | View details for Leerink Partners rating of GoodRx (NASDAQ:GDRX) on 8/6/2026 |
EXEL Exelixis | $64.53 -1.2% | 8/6/2026 | | Downgrade | $52.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Exelixis (NASDAQ:EXEL) on 8/6/2026 |
PODD Insulet | $149.01 +0.6% | 8/6/2026 | | Downgrade | $247.00 ➝ $145.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 8/6/2026 |
ABBV AbbVie | $285.66 +0.2% | 8/5/2026 | | Boost Price Target | $245.00 ➝ $279.00 | Outperform | 00.00% | View details for Leerink Partners rating of AbbVie (NYSE:ABBV) on 8/5/2026 |
REPL Replimune Group | $11.46 -4.4% | 8/4/2026 | | Upgrade | $11.00 ➝ $17.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 8/4/2026 |
KROS Keros Therapeutics | $11.28 -0.6% | 8/4/2026 | | Lower Price Target | $30.00 ➝ $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Keros Therapeutics (NASDAQ:KROS) on 8/4/2026 |
LNTH Lantheus | $99.80 -0.3% | 8/3/2026 | | Set Price Target | $102.50 | | 00.00% | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026 |
INCY Incyte | $115.71 -1.0% | 8/3/2026 | | Boost Price Target | $131.00 ➝ $155.00 | Outperform | 00.00% | View details for Leerink Partners rating of Incyte (NASDAQ:INCY) on 8/3/2026 |
LNTH Lantheus | $99.80 -0.3% | 8/3/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026 |
BMY Bristol Myers Squibb | $61.58 -2.3% | 7/31/2026 | | Boost Price Target | $67.00 ➝ $73.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bristol Myers Squibb (NYSE:BMY) on 7/31/2026 |